JERSEY CITY, N.J.–(BUSINESS WIRE)–Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative treatments for patients with age-related macular degeneration (AMD). This relationship, initiated in 2024, represents a major step forward by bringing together Bausch + Lomb’s extensive expertise in ophthalmology with Character Bio’s integrated patient data platform a
Go to Source
Author: